Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

Ophthalmology

Volumn 119, Issue 8, 2012, Pages 1679-1684

  Dewan, Vinay ^a   Lambert, Dennis ^a   Edler, Joshua ^a   Kymes, Steven ^a   Apte, Rajendra S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE;

ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; INTERNAL VALIDITY; LOW LEVEL LASER THERAPY; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84864473215     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.049     Document Type: Article

References (20)

1. G.H. Bresnik Diabetic macular edema: a review Ophthalmology 93 1986 989 997
2. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
3. M.J. Elman, L.P. Aiello, R.W. Beck Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
4. K. Baicker, J.S. Skinner Health Care Spending Growth and the Future of U.S. Tax Rates NBER Working Paper no. 16772 February 2011 http://www.nber.org/ papers/w16772 Accessed January 4, 2012
5. D.B. Rein, P. Zhang, K.E. Wirth The economic burden of major adult visual disorders in the United States Arch Ophthalmol 124 2006 1754 1760
6. D. Smith, P. Fenn, M. Drummond Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case Br J Ophthalmol 88 2004 1107 1112
7. S.M. Kymes An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases Ophthalmic Epidemiol 15 2008 76 83
8. S. Sharma, G.C. Brown, M.M. Brown The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis Curr Opin Ophthalmol 11 2000 175 179
9. J.C. Javitt, L.P. Aiello Cost-effectiveness of detecting and treating diabetic retinopathy Ann Intern Med 124 1996 164 169
10. M. Gold, P. Franks, P. Erickson Assessing the health of the nation: The predictive validity of a preference-based measure and self-rated health Med Care 34 1996 163 177
11. P.J. Neumann, M.C. Weinstein Legislating against use of cost-effectiveness information N Engl J Med 363 2010 1495 1497
12. J.A. Haller, F. Bandello, R. Belfort Jr OZURDEX GENEVA Study Group Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion Ophthalmology 117 2010 1134 1146
13. B.G. Busbee, M.M. Brown, G.C. Brown, S. Sharma Cost-utility analysis of cataract surgery in the second eye Ophthalmology 110 2003 2310 2317
14. N.R. Rylander Cost analysis of glaucoma medications Am J Ophthalmol 145 2008 106 113
15. P.J. Neumann Lessons for health technology assessment: it is not only about the evidence Value Health 12 Suppl 2009 S45 S48
16. A. Wailoo, J. Roberts, J. Brazier, C. McCabe Efficiency, equity, and NICE clinical guidelines BMJ 328 2004 536 537
17. Patient Protection and Affordable Care Act 42 USC §18001 (2010) http://www.ihs.gov/adminmngrresources/ihcia/documents/PL111-148.pdf Accessed January 4, 2012
18. P.A. Ubel, R.A. Hirth, M.E. Chernew, A.M. Fendrick What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 2003 1637 1641
19. C. Kaiser, H.P. Brunner-La Rocca, P.T. Buser BASKET Investigators Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial Lancet 366 2005 921 929
20. M.K. Gould, G.D. Sanders, P.G. Barnett Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules Ann Intern Med 138 2003 724 735